Drug Profile
ADPS topical - Taro Pharmaceuticals USA
Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Taro Pharmaceuticals USA
- Class Antiacnes; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acne vulgaris
Most Recent Events
- 22 Feb 2022 No development reported - Phase-II for Acne vulgaris (In adolescents, In children, In adults) in USA (Topical)
- 01 Apr 2017 Taro Pharmaceuticals completes a phase II trial in Acne vulgaris (In children, In adolescents, In adults) in USA (NCT02935036)
- 01 Oct 2016 Phase-II clinical trials in Acne vulgaris (In children, In adolescents, In adults) in USA (Topical) (NCT02935036)